Quantcast

BMS’s lirilumab could complement nivolumab or ipilimumab?

Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.

Read more